General Information of Drug Transporter (DT)
DT ID	DTD0034 Transporter Info
Gene Name	SLC18A2
Protein Name	Vesicular amine transporter 2
Gene ID	6571
UniProt ID	Q05940
Genetic Polymorphisms of DT (GPD)
Genetic Polymorphism	rs363341
Site of GPD	chr10:117250954 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>T
Minor Allele Frequency	T=0.3982/1994 (Global)
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Antipsychotics	N.A.	Drug Toxicity	Genotype TT is associated with increased risk of Drug Toxicity when treated with antipsychotics in people with Psychotic Disorders as compared to genotypes CC + CT.		[ 1]
Antipsychotics	N.A.	Psychotic Disorder	Genotype TT is associated with increased risk of Drug Toxicity when treated with antipsychotics in people with Psychotic Disorders as compared to genotypes CC + CT.		[ 1]
Antipsychotics	N.A.	Psychotic Disorders	Correlated with the increased drug toxicity risk in patients (compare with genotypes CC + CT)		[ 1]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Antipsychotics	N.A.	Psychotic Disorder	Patients with the CC genotype and first episode psychosis (FEP) may have a decreased risk for extrapyramidal symptoms when treated with antipsychotics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of extrapyramidal symptoms.		[ 1]
Genotype CT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Antipsychotics	N.A.	Psychotic Disorder	Patients with the CT genotype and first episode psychosis (FEP) may have a decreased risk for extrapyramidal symptoms when treated with antipsychotics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of extrapyramidal symptoms.		[ 1]
Genetic Polymorphism	rs363225
Site of GPD	chr10:117264991 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>A / C>G / C>T
Minor Allele Frequency	C=0.5960/1179 (Global)
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Bupropion	N.A.	Asthma	Genotype CC is associated with increased response to bupropion in people with Depressive Disorder, Major as compared to genotypes CT + TT.		[ 2]
Bupropion	N.A.	Major Depressive Disorder	Genotype CC is associated with increased response to bupropion in people with Depressive Disorder, Major as compared to genotypes CT + TT.		[ 2]
Genotype CT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Bupropion	N.A.	Major Depressive Disorder	Patients with the CT genotype may have a decreased response to bupropion in the treatment of major depressive disorder, as measured by a reduction in HAMD scores, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to bupropion.		[ 2]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Bupropion	N.A.	Major Depressive Disorder	Patients with the TT genotype may have a decreased response to bupropion in the treatment of major depressive disorder, as measured by a reduction in HAMD scores, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to bupropion.		[ 2]
Genetic Polymorphism	rs363226
Site of GPD	chr10:117265701 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A / G>C / G>T
Minor Allele Frequency	G=0.2900/573 (Global)
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Bupropion	N.A.	Asthma	Genotype GG is associated with increased response to bupropion in people with Depressive Disorder, Major as compared to genotypes CC + CG.		[ 2]
Bupropion	N.A.	Major Depressive Disorder	Genotype GG is associated with increased response to bupropion in people with Depressive Disorder, Major as compared to genotypes CC + CG.		[ 2]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Bupropion	N.A.	Major Depressive Disorder	Patients with the CC genotype may have a decreased response to bupropion in the treatment of major depressive disorder, as measured by a reduction in HAMD scores, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to bupropion.		[ 2]
Genotype CG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Bupropion	N.A.	Major Depressive Disorder	Patients with the CG genotype may have a decreased response to bupropion in the treatment of major depressive disorder, as measured by a reduction in HAMD scores, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to bupropion.		[ 2]
Genetic Polymorphism	rs363371
Site of GPD	chr10:117226885 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A
Minor Allele Frequency	G=0.7460/1476 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Citalopram	N.A.	Drug Toxicity	Allele A is not associated with response to citalopram in people with Depressive Disorder, Major as compared to allele G.		[ 3]
Genetic Polymorphism	rs363390
Site of GPD	chr10:117244568 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A / G>C
Minor Allele Frequency	G=0.7570/1498 (Global)
Allele C	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Citalopram	N.A.	Drug Toxicity	Allele C is not associated with response to citalopram in people with Depressive Disorder, Major as compared to allele G.		[ 3]
Genotypes CC + CG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Antipsychotics	N.A.	Tardive Dyskinesia	Genotypes CC + CG is associated with increased risk of tardive dyskinesia when treated with antipsychotics in people with schizoaffective disorder and Schizophrenia as compared to genotype GG.		[ 4]
Genetic Polymorphism	rs363343
Site of GPD	chr10:117255437 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>A
Minor Allele Frequency	C=0.3610/714 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Citalopram	N.A.	Drug Toxicity	Allele A is not associated with response to citalopram in people with Depressive Disorder, Major as compared to allele C.		[ 3]
Genetic Polymorphism	rs929493
Site of GPD	chr10:117259615 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>T
Minor Allele Frequency	C=0.4140/819 (Global)
Allele C	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Citalopram	N.A.	Drug Toxicity	Allele C is not associated with response to citalopram in people with Depressive Disorder, Major as compared to allele T.		[ 3]
Genetic Polymorphism	rs14240
Site of GPD	chr10:117277560 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>A / T>C / T>G
Minor Allele Frequency	T=0.5510/1090 (Global)
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Antipsychotics	N.A.	Tardive Dyskinesia	Genotype TT is associated with increased risk of tardive dyskinesia when treated with antipsychotics in people with schizoaffective disorder and Schizophrenia as compared to genotypes CC + CT.		[ 4]
Genetic Polymorphism	rs363224
Site of GPD	chr10:117263062 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>A / C>T
Minor Allele Frequency	C=0.5510/1090 (Global)
Genotypes AC + CC	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Antipsychotics	N.A.	Tardive Dyskinesia	Genotypes AC + CC is associated with increased risk of tardive dyskinesia when treated with antipsychotics in people with schizoaffective disorder and Schizophrenia as compared to genotype AA.		[ 4]
Genetic Polymorphism	rs363332
Site of GPD	chr10:117243156 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A / G>T
Minor Allele Frequency	G=0.7590/1502 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Opioids	N.A.	Opioid-related Disorders	Allele A is associated with increased likelihood of Opioid-Related Disorders when exposed to opioids as compared to allele G.		[ 5]
Genetic Polymorphism	rs363334
Site of GPD	chr10:117245484 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>G
Minor Allele Frequency	C=0.6890/1363 (Global)
Allele G	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Opioids	N.A.	Opioid-related Disorders	Allele G is associated with increased likelihood of Opioid-Related Disorders when exposed to opioids.		[ 5]
Genetic Polymorphism	rs363338
Site of GPD	chr10:117249878 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>A / C>G / C>T
Minor Allele Frequency	C=0.5390/1066 (Global)
Allele C	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Opioids	N.A.	Opioid-related Disorders	Allele C is associated with increased likelihood of Opioid-Related Disorders when exposed to opioids as compared to allele T.		[ 5]
References
1	Pharmacogenetic study of antipsychotic induced acute extrapyramidal symptoms in a first episode psychosis cohort: role of dopamine, serotonin and glutamate candidate genes. Pharmacogenomics J. 2016 Oct;16(5):439-45.
2	Analysis of 34 candidate genes in bupropion and placebo remission. Int J Neuropsychopharmacol. 2013 May;16(4):771-81.
3	Variation in the genes encoding vesicular monoamine transporter 2 and beta-1 adrenergic receptor and antidepressant treatment outcome. Psychiatr Genet. 2008 Oct;18(5):248-51.
4	Association study of the vesicular monoamine transporter gene SLC18A2 with tardive dyskinesia. J Psychiatr Res. 2013 Nov;47(11):1760-5.
5	VMAT2 gene (SLC18A2) variants associated with a greater risk for developing opioid dependence. Pharmacogenomics. 2019 Apr;20(5):331-341.

If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.